-+ 0.00%
-+ 0.00%
-+ 0.00%

PDS Biotech reports 78% response rate in interim Phase 2 colorectal cancer trial

PUBT·04/15/2026 12:45:32
Listen to the news
PDS Biotech reports 78% response rate in interim Phase 2 colorectal cancer trial
  • PDS Biotech reported publication of interim Phase 2 data on March 10, 2026 in JCO Oncology Advances for PDS01ADC in metastatic colorectal cancer with liver metastases.
  • Results were already presented via the journal publication, covering Stage 1 of an NCI-led study combining PDS01ADC with hepatic artery infusion pump therapy using floxuridine.
  • Patients receiving PDS01ADC showed markedly stronger tumor shrinkage versus outcomes cited from a separate, parallel study that did not use PDS01ADC.
  • Survival outcomes appeared substantially improved, with disease control outside liver also trending better in the interim analysis.
  • Data support continued development of PDS01ADC in microsatellite-stable or mismatch repair-proficient disease, a large segment where checkpoint inhibitors have largely failed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150845PRIMZONEFULLFEED9690014) on April 15, 2026, and is solely responsible for the information contained therein.